# A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

> **NCT05314517** · PHASE2 · TERMINATED · sponsor: **Kinevant Sciences GmbH** · enrollment: 107 (actual)

## Conditions studied

- Sarcoidosis, Pulmonary

## Interventions

- **DRUG:** Namilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05314517
- **Lead sponsor:** Kinevant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-31
- **Primary completion:** 2024-10-16
- **Final completion:** 2025-04-09
- **Target enrollment:** 107 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05314517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05314517, "A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05314517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*